327 related articles for article (PubMed ID: 21610512)
1. Effect of the plasminogen-plasmin system on hypertensive renal and cardiac damage.
Knier B; Cordasic N; Klanke B; Heusinger-Ribeiro J; Daniel C; Veelken R; Hartner A; Hilgers KF
J Hypertens; 2011 Aug; 29(8):1602-12. PubMed ID: 21610512
[TBL] [Abstract][Full Text] [Related]
2. Pharmacological inhibition and genetic deficiency of plasminogen activator inhibitor-1 attenuates angiotensin II/salt-induced aortic remodeling.
Weisberg AD; Albornoz F; Griffin JP; Crandall DL; Elokdah H; Fogo AB; Vaughan DE; Brown NJ
Arterioscler Thromb Vasc Biol; 2005 Feb; 25(2):365-71. PubMed ID: 15576638
[TBL] [Abstract][Full Text] [Related]
3. Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/NG-nitro-L-arginine methyl ester-induced myocardial injury.
Oestreicher EM; Martinez-Vasquez D; Stone JR; Jonasson L; Roubsanthisuk W; Mukasa K; Adler GK
Circulation; 2003 Nov; 108(20):2517-23. PubMed ID: 14581407
[TBL] [Abstract][Full Text] [Related]
4. Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury.
Ma J; Weisberg A; Griffin JP; Vaughan DE; Fogo AB; Brown NJ
Kidney Int; 2006 Mar; 69(6):1064-72. PubMed ID: 16528256
[TBL] [Abstract][Full Text] [Related]
5. Regulation of gelatinase activity in mice with targeted inactivation of components of the plasminogen/plasmin system.
Lijnen HR; Silence J; Lemmens G; Frederix L; Collen D
Thromb Haemost; 1998 Jun; 79(6):1171-6. PubMed ID: 9657444
[TBL] [Abstract][Full Text] [Related]
6. Type 1 plasminogen activator inhibitor deficiency aggravates the course of experimental glomerulonephritis through overactivation of transforming growth factor beta.
Hertig A; Berrou J; Allory Y; Breton L; Commo F; Costa De Beauregard MA; Carmeliet P; Rondeau E
FASEB J; 2003 Oct; 17(13):1904-6. PubMed ID: 12897066
[TBL] [Abstract][Full Text] [Related]
7. Plasmin-dependent and -independent effects of plasminogen activators and inhibitor-1 on ex vivo angiogenesis.
Brodsky S; Chen J; Lee A; Akassoglou K; Norman J; Goligorsky MS
Am J Physiol Heart Circ Physiol; 2001 Oct; 281(4):H1784-92. PubMed ID: 11557572
[TBL] [Abstract][Full Text] [Related]
8. [The influence of I/D polymorphism of the angiotensin I converting enzyme (ACE) gene and 4G/5G polymorphism of plasminogen activator inhibitor (PAI-1) gene promoter on the haemostatic system in patients with essential hypertension and dyslipidemia].
Nowakowska A
Ann Acad Med Stetin; 2005; 51(1):95-105. PubMed ID: 16496609
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of urokinase by macrophages or deficiency of plasminogen activator inhibitor type 1 causes cardiac fibrosis in mice.
Moriwaki H; Stempien-Otero A; Kremen M; Cozen AE; Dichek DA
Circ Res; 2004 Sep; 95(6):637-44. PubMed ID: 15297377
[TBL] [Abstract][Full Text] [Related]
10. Plasminogen Activator Inhibitor-1 Protects Mice Against Cardiac Fibrosis by Inhibiting Urokinase-type Plasminogen Activator-mediated Plasminogen Activation.
Gupta KK; Donahue DL; Sandoval-Cooper MJ; Castellino FJ; Ploplis VA
Sci Rep; 2017 Mar; 7(1):365. PubMed ID: 28336948
[TBL] [Abstract][Full Text] [Related]
11. Angiotensin II increases plasminogen activator inhibitor type 1 and tissue-type plasminogen activator messenger RNA in cultured rat aortic smooth muscle cells.
van Leeuwen RT; Kol A; Andreotti F; Kluft C; Maseri A; Sperti G
Circulation; 1994 Jul; 90(1):362-8. PubMed ID: 8026020
[TBL] [Abstract][Full Text] [Related]
12. The role of fibrinolytic genes and proteins in the development of allograft vascular disease.
Benza RL; Passineau MJ; Anderson PG; Barchue JP; George JF
J Heart Lung Transplant; 2011 Aug; 30(8):935-44. PubMed ID: 21652221
[TBL] [Abstract][Full Text] [Related]
13. Physiological regulation of MMPs and tPA/PAI in the arterial wall of rats by noradrenergic tone and angiotensin II.
Dab H; Hachani R; Dhaouadi N; Hodroj W; Sakly M; Randon J; Bricca G; Kacem K
J Renin Angiotensin Aldosterone Syst; 2012 Mar; 13(1):36-45. PubMed ID: 22071631
[TBL] [Abstract][Full Text] [Related]
14. Transcriptional profiling after bile duct ligation identifies PAI-1 as a contributor to cholestatic injury in mice.
Wang H; Vohra BP; Zhang Y; Heuckeroth RO
Hepatology; 2005 Nov; 42(5):1099-108. PubMed ID: 16250054
[TBL] [Abstract][Full Text] [Related]
15. Effect of combined angiotensin-converting enzyme and aldosterone inhibition on plasma plasminogen activator inhibitor type 1 levels in chronic hypertensive patients.
Tiryaki O; Usalan C; Buyukhatipoglu H
Nephrology (Carlton); 2010 Mar; 15(2):211-5. PubMed ID: 20470281
[TBL] [Abstract][Full Text] [Related]
16. The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent.
Devy L; Blacher S; Grignet-Debrus C; Bajou K; Masson V; Gerard RD; Gils A; Carmeliet G; Carmeliet P; Declerck PJ; Nöel A; Foidart JM
FASEB J; 2002 Feb; 16(2):147-54. PubMed ID: 11818362
[TBL] [Abstract][Full Text] [Related]
17. Potential roles of plasminogen activator system in coronary vascular remodeling induced by long-term nitric oxide synthase inhibition.
Kaikita K; Schoenhard JA; Painter CA; Ripley RT; Brown NJ; Fogo AB; Vaughan DE
J Mol Cell Cardiol; 2002 Jun; 34(6):617-27. PubMed ID: 12054849
[TBL] [Abstract][Full Text] [Related]
18. Circadian expression of plasminogen activator inhibitor-1 in angiotensin II type 1a receptor knockout mice.
Tsujino T; Naito Y; Kawasaki D; Okuda S; Sakoda T; Fujioka Y; Sugaya T; Ohyanagi M
Clin Exp Hypertens; 2005; 27(2-3):159-68. PubMed ID: 15835378
[TBL] [Abstract][Full Text] [Related]
19. Targeting the calpain/calpastatin system as a new strategy to prevent cardiovascular remodeling in angiotensin II-induced hypertension.
Letavernier E; Perez J; Bellocq A; Mesnard L; de Castro Keller A; Haymann JP; Baud L
Circ Res; 2008 Mar; 102(6):720-8. PubMed ID: 18258859
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin IV stimulates plasminogen activator inhibitor-1 expression in proximal tubular epithelial cells.
Gesualdo L; Ranieri E; Monno R; Rossiello MR; Colucci M; Semeraro N; Grandaliano G; Schena FP; Ursi M; Cerullo G
Kidney Int; 1999 Aug; 56(2):461-70. PubMed ID: 10432384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
